Drugs / Triac
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02060474 | Oct 2014 → Jun 2018 | Allan-Herndon-Dudley syndrome | Erasmus Medical Center | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-06-19 | Egetis Therapeutics | Egetis announces topline results of the Phase 2 Triac Trial II with Emcitate® (tiratricol) for MCT8 deficiency egetis.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triac | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02060474 ↗ |
| Known as | 3,3',5-tri-iodothyroacetic acid | “Treatment that safely alleviates peripheral thyrotoxicosis and reverses cerebral hypothyroidism is not yet available. We aimed to investigate the effects of treatment with the...” PMID 31377265 ↗ Jul 2019 |
| Modality | Small molecule | “Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.” NCT02060474 ↗ |
| Route | Oral | “effectiveness and safety of oral Triac” PMID 31377265 ↗ Jul 2019 |